In this opinion piece from our Editor, Jade Parker, you can discover the top 5 breast cancer advancements of 2018.
Browsing: Disease Area > Breast
A combination of the targeted drug vistusertib with paclitaxel chemotherapy has shown promise in an early clinical trial, in patients with ovarian or lung cancer for whom all other treatments had failed.
Find out exclusive insights about the career of V. Craig Jordan who is considered the “father of tamoxifen” as well as details of the research areas he and his mentee Balkees Abderrahman are investigating.
Student aims to 3D print breast cancer tumors in an attempt to provide faster and more effective treatment for the disease.
Specific genes associated with triple-negative breast cancer risk have been identified by multigene hereditary cancer panel testing.
A Phase 1b clinical trial investigating tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2/HER2-positive metastatic breast cancer has yielded encouraging results.
The Phase III IMpassion130 study, investigating TECENTRIQ® plus Abraxane® for triple-negative breast cancer, has met its progression-free survival endpoint.
We have brought together our top takeaways from the five days of ASCO 2018.
In a medical breakthrough, a new approach to immunotherapy has led to complete regression of breast cancer in a patient unresponsive to all other treatments.